StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)

Close on Nov 18, 2026Market cap $23.87MP/E –Yield –

Metagenomi Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Metagenomi Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$85.80M. For fiscal 2025 it was -$89.47M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$89.47M–
FY2024Dec 31, 2024-$112.19M–
FY2023Dec 31, 2023-$101.22M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.64M–
Q1 FY2026Mar 31, 2026-$21.20M–
Q4 FY2025Dec 31, 2025-$23.63M–
Q3 FY2025Sep 30, 2025-$21.33M–
Q2 FY2025Jun 30, 2025-$21.38M–
Q1 FY2025Mar 31, 2025-$23.13M–
Q4 FY2024Dec 31, 2024-$26.61M–
Q3 FY2024Sep 30, 2024-$27.84M–
Q2 FY2024Jun 30, 2024-$26.97M–
Q1 FY2024Mar 31, 2024-$30.77M–
Q4 FY2023Dec 31, 2023-$22.33M–
Q3 FY2023Sep 30, 2023-$25.99M–
Q2 FY2023Jun 30, 2023-$29.24M–
Q1 FY2023Mar 31, 2023-$23.66M–

More Metagenomi Therapeutics figures

See a number that looks wrong?